EP4164653A4 - Formes morphiques de trilaciclib et leurs procédés de fabrication - Google Patents

Formes morphiques de trilaciclib et leurs procédés de fabrication Download PDF

Info

Publication number
EP4164653A4
EP4164653A4 EP21826036.2A EP21826036A EP4164653A4 EP 4164653 A4 EP4164653 A4 EP 4164653A4 EP 21826036 A EP21826036 A EP 21826036A EP 4164653 A4 EP4164653 A4 EP 4164653A4
Authority
EP
European Patent Office
Prior art keywords
trilaciclib
manufacturing
methods
morphic forms
morphic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21826036.2A
Other languages
German (de)
English (en)
Other versions
EP4164653A1 (fr
Inventor
Stephen Schneider
Alexander Smith
Hannah S. WHITE
Jay Copeland Strum
Jaroslaw Mazurek
Sara WU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacosmos Holding AS
Original Assignee
G1 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/097,854 external-priority patent/US10988479B1/en
Application filed by G1 Therapeutics Inc filed Critical G1 Therapeutics Inc
Publication of EP4164653A1 publication Critical patent/EP4164653A1/fr
Publication of EP4164653A4 publication Critical patent/EP4164653A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21826036.2A 2020-06-15 2021-06-15 Formes morphiques de trilaciclib et leurs procédés de fabrication Pending EP4164653A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063039372P 2020-06-15 2020-06-15
US17/097,854 US10988479B1 (en) 2020-06-15 2020-11-13 Morphic forms of trilaciclib and methods of manufacture thereof
US202163180578P 2021-04-27 2021-04-27
PCT/US2021/037462 WO2021257587A1 (fr) 2020-06-15 2021-06-15 Formes morphiques de trilaciclib et leurs procédés de fabrication

Publications (2)

Publication Number Publication Date
EP4164653A1 EP4164653A1 (fr) 2023-04-19
EP4164653A4 true EP4164653A4 (fr) 2024-06-19

Family

ID=80326310

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21826036.2A Pending EP4164653A4 (fr) 2020-06-15 2021-06-15 Formes morphiques de trilaciclib et leurs procédés de fabrication

Country Status (4)

Country Link
EP (1) EP4164653A4 (fr)
CN (2) CN120398896A (fr)
TW (1) TWI906312B (fr)
WO (1) WO2021257587A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4225758B1 (fr) * 2020-10-08 2025-11-26 Assia Chemical Industries Ltd. Formes à l'état solide de trilaciclib et de sels de trilaciclib
US20250136610A1 (en) 2022-02-28 2025-05-01 Teva Pharmaceuticals International Gmbh Crystalline forms of trilaciclib and trilaciclib salts
WO2024009319A1 (fr) * 2022-07-02 2024-01-11 Dr. Reddy's Laboratories Limited Compositions injectables liquides de trilaciclib
IT202300010182A1 (it) * 2023-05-19 2024-11-19 Olon Spa Forma solvata di trilaciclib di-cloridrato.
IT202300010824A1 (it) * 2023-05-29 2024-11-29 Olon Spa Forma solvata di trilaciclib di-cloridrato.
WO2025134057A1 (fr) 2023-12-20 2025-06-26 Assia Chemical Industries Ltd. Formes à l'état solide de sel de citrate de trilaciclib

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8598186B2 (en) * 2010-10-25 2013-12-03 G1 Therapeutics, Inc. CDK inhibitors
US20160220569A1 (en) * 2015-02-03 2016-08-04 G1 Therapeutics, Inc. CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
WO2018005865A1 (fr) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Synthèse de n-(hétéroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
UA68365C2 (en) 1997-11-06 2004-08-16 Wyeth Corp Peroral contraception by combination of anti-estrogen and progestin
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
US6583170B1 (en) 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
CO5271696A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
US20020013327A1 (en) 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
WO2002003988A2 (fr) 2000-07-06 2002-01-17 Wyeth Methodes permettant de traiter de troubles associes au neuropeptide y -
AU2001271706A1 (en) 2000-07-06 2002-01-21 American Home Products Corporation Use of substituted indole compounds for treating breast disorders
US6509332B2 (en) 2000-07-06 2003-01-21 Wyeth Methods of treating excessive intraocular pressure
EP1296674A2 (fr) 2000-07-06 2003-04-02 Wyeth Methodes permettant d'accroitre l'activite d'oxyde nitrique- synthase
AU2001271784A1 (en) 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
JP2004502729A (ja) 2000-07-06 2004-01-29 ワイス Ｓｓｒｉおよびエストロゲン剤の組み合わせ
AR030064A1 (es) 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
AU2001273125A1 (en) 2000-07-06 2002-01-21 American Home Products Corporation Combinations of bisphosphonates, estrogenic agents and optionally estrogens
EP1359940A2 (fr) 2000-07-06 2003-11-12 Wyeth Combinaisons de statines, d'agents oestrogeniques et eventuellement d'oestrogenes
WO2002003989A2 (fr) 2000-07-06 2002-01-17 Wyeth Therapie permettant d'inhiber l'incontinence du sphincter
EP1177787A3 (fr) 2000-07-28 2003-09-10 Pfizer Products Inc. Utilisation d'un agoniste/antagoniste estrogénique pour traiter la cataracte
ATE278421T1 (de) 2000-08-11 2004-10-15 Wyeth Corp Verfahren zur behandlung eines östrogenrezeptor positives karzinoms
EP1192945A3 (fr) 2000-09-21 2004-03-03 Pfizer Products Inc. Utilisation d'un agoniste/antagoniste estrogénique pour traiter l'ostéoarthrite
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
US7399767B2 (en) 2005-01-21 2008-07-15 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
CA2640678C (fr) 2006-02-03 2015-03-31 Bionomics Limited Benzofurannes, benzothiophenes, benzoselenophenes et indoles substitues et leur emploi en tant qu'inhibiteurs de la polymerisation de la tubuline
CN102713618B (zh) 2009-09-16 2015-07-15 新基阿维罗米克斯研究公司 蛋白激酶复合物和抑制剂
EP3205648A1 (fr) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Modulateur du récepteur oestrogénique et utilisation de ces derniers
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US10005750B2 (en) 2010-10-06 2018-06-26 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
CA2819299A1 (fr) 2010-12-24 2012-06-28 Merck Sharp & Dohme B.V. Derives d'azetidine n-substitues
EP2791132A4 (fr) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc Modulateurs des récepteurs des strogènes et ses utilisations
BR112014014767A2 (pt) 2011-12-16 2017-06-13 Olema Pharmaceuticals Inc novos compostos de benzopirano, composições e usos dos mesmos
CN104145514B (zh) 2012-08-01 2018-03-13 华为技术有限公司 用于同步的方法、装置及系统
JP6430483B2 (ja) * 2013-03-15 2018-11-28 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 化学療法の間の正常細胞の一時的な保護
AP2015008858A0 (en) 2013-05-28 2015-11-30 Astrazeneca Ab Chemical compounds
WO2014203132A1 (fr) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Composés de benzopyran substitués, leurs compositions et utilisations
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
WO2014203129A1 (fr) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinaisons de composés benzopyrane, leurs compositions et utilisations
SG11201607334YA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
TWI784255B (zh) 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
IL317919A (en) * 2016-12-05 2025-02-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
EP3645001B1 (fr) * 2017-06-29 2024-07-03 G1 Therapeutics, Inc. Formes morphiques de git38 et leurs procédés de fabrication
KR102962306B1 (ko) 2018-08-24 2026-05-08 쥐원 쎄라퓨틱스, 인크. 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성
US10988479B1 (en) * 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8598186B2 (en) * 2010-10-25 2013-12-03 G1 Therapeutics, Inc. CDK inhibitors
US20160220569A1 (en) * 2015-02-03 2016-08-04 G1 Therapeutics, Inc. CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
WO2018005865A1 (fr) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Synthèse de n-(hétéroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021257587A1 *

Also Published As

Publication number Publication date
CN120398896A (zh) 2025-08-01
TW202214650A (zh) 2022-04-16
EP4164653A1 (fr) 2023-04-19
WO2021257587A1 (fr) 2021-12-23
CN116157403A (zh) 2023-05-23
TWI906312B (zh) 2025-12-01
CN116157403B (zh) 2025-04-25

Similar Documents

Publication Publication Date Title
EP3924159A4 (fr) Ancres ventouses et leurs procédés de fabrication
EP4288831A4 (fr) Structures périodiques évacuées et leurs procédés de fabrication
EP4049046A4 (fr) Cellules à vapeur ayant des sections transversales de diffusion réduites et leurs procédés de fabrication
EP3867936A4 (fr) Éponges nano-graphitiques et leurs procédés de fabrication
EP4022679A4 (fr) Ensembles intégrés et leurs procédés de formation
EP3857612A4 (fr) Dispositifs optoélectroniques et leurs procédés de fabrication
EP4329632A4 (fr) Compositions et leurs procédés de production
EP4093407A4 (fr) Arn à double brin thérapeutique et leurs procédés de fabrication
MA71245A (fr) Procédés de fabrication d'inhibiteurs de btk modifiés
EP3413710A4 (fr) Surfaces structurées antibactériennes et leurs procédés de fabrication
EP4377314A4 (fr) Inhibiteurs de pgdh bicycliques et leurs procédés de fabrication et d'utilisation
EP4192247A4 (fr) Compositions antibactériennes et leurs procédés de fabrication
EP4410410A4 (fr) Séparateur et son procédé de fabrication
EP3930862A4 (fr) Composition et procédés de fabrication de grips
PL4266504T3 (pl) Zespół zaciskowy i sposób jego wytwarzania
EP3891840A4 (fr) Structures à cavités multicouches et leurs procédés de fabrication
EP3930155A4 (fr) Joint de bobine et procédé de fabrication de joint de bobine
EP3469137A4 (fr) Surfaces hydrophobes et hydrophiles, articles et leurs procédés de fabrication
IL313212A (en) Solid state forms of tavapadon and processes for preparation thereof
EP4419619A4 (fr) Composition et procédé pour gravure humide sélective
PL4215382T3 (pl) Sposób wytwarzania panelu
EP3975252A4 (fr) Structure semi-conductrice et procédé de fabrication de structure semi-conductrice
EP4082929A4 (fr) Tôle métallique revêtue de résine et boîte emboutie-étirée revêtue de résine et leurs procédés de fabrication
EP4528261A4 (fr) Biocapteur et procédé de préparation s'y rapportant
EP4017884A4 (fr) Compositions d'anticorps igg et leurs procédés de fabrication

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230104

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230524

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40091353

Country of ref document: HK

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031519000

Ipc: C07D0487220000

A4 Supplementary search report drawn up and despatched

Effective date: 20240517

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/519 20060101ALI20240514BHEP

Ipc: C07D 487/22 20060101AFI20240514BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHARMACOSMOS HOLDING A/S

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20260227